This regimen should be studied in patients with advanced ACC, especially tumors with higher expression of Ki67, MELK, CDK1, CDK2, their partnering cyclins, FOXM1, STMN1, and CTNNB1. The gene discussed is FOXM1; the disease is adrenal cortex carcinoma.